![Christopher Jewell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christopher Jewell
Geen lopende functies
Vermogen: 790 773 $ op 31-05-2026
Profiel
Christopher Jewell worked as a Professor at the University of Maryland from 2020 to 2024.
Dr. Jewell served as Chief Scientific Officer at Cartesian Therapeutics, Inc. (United States) in 2023 and continued in the same role at Cartesian Therapeutics, Inc. from 2023 to 2025.
Dr. Jewell earned a doctorate from the University of Wisconsin.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
0,36% | 14-04-2026 | 104.877 ( 0,36% ) | 790 773 $ | 31-05-2026 |
Eerdere bekende functies van Christopher Jewell
| Bedrijven | Functie | Einde |
|---|---|---|
University of Maryland
 University of Maryland Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01-04-2024 |
Cartesian Therapeutics, Inc.
 Cartesian Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage company that develops mRNA cell therapies for autoimmune diseases | Hoofd Techniek/Wetenschap/O&O | 13-11-2023 |
Opleiding van Christopher Jewell
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
29
Eerstegraads connecties
3
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
University of Wisconsin
 University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Maryland
University of Maryland Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage company that develops mRNA cell therapies for autoimmune diseases | Commercial Services |
